Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases
  4. Growth and resilience in a challenging environment – Siemens Healthineers raises outlook again
Press release

Growth and resilience in a challenging environment – Siemens Healthineers raises outlook again

Siemens Healthineers AG today announces its results for the fiscal year 2022 second quarter that ended March 31, 2022.
Published on May 4, 2022

Q2 Fiscal Year 2022

  • Continued very good growth in orders and revenue in the second quarter: equipment book-to-bill ratio of 1.22 and comparable revenue growth of 15.8%
  • Diagnostics achieved outstanding comparable revenue growth of 37.2%; revenue of almost €680 million from rapid COVID-19 antigen tests
  • Substantial comparable revenue growth of 6.5% in Imaging and 7.6% in Advanced Therapies
  • Varian with a revenue contribution of €706 million and a strong equipment book-to-bill ratio of 1.31
  • Adjusted EBIT margin of 17.9% due to higher contributions from rapid COVID-19 antigen tests; currency effects and higher procurement and logistics costs had a negative impact
  • Adjusted basic earnings per share up 53% to €0.67

Updated Outlook for Fiscal Year 2022

Due to the further increased demand for rapid COVID-19 antigen tests, we again raise our outlook for fiscal year 2022. The outlook is now based on the assumption that the Diagnostics segment will generate around €1.3 billion (previously around €700 million) in revenue with rapid COVID-19 antigen tests. As a result, we now expect comparable revenue growth between 5.5% and 7.5% (previously 3% to 5%) and adjusted basic earnings per share between €2.25 and €2.35 (previously €2.18 to €2.30).

Bernd Montag, CEO of Siemens Healthineers AG:

»Our purpose is to pioneer breakthroughs in healthcare for everyone, everywhere – especially in times like these. Our business continues to show great resilience in the face of unprecedented challenges. On this foundation, and thanks to high demand for our rapid antigen tests, we are raising our outlook for the current financial year.«

Download Quarterly Statement(pdf, 187.38 KB)

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.